What is key when describing liver lesions on CT or MRI for characterization and follow-up?

What is key when describing liver lesions on CT or MRI for characterization and follow-up?

• A. Describe size, number, enhancement pattern, washout, diffusion characteristics, and suggest follow-up imaging or MRI for further characterization if indeterminate.
• B. Describe only size.
• C. Exclude diffusion characteristics.
• D. Rely solely on CT attenuation without enhancement information.

Answer: (C)

Describing liver lesions on CT or MRI must be comprehensive and systematic, because imaging features across phases guide diagnosis and management. The most informative report includes lesion size and number, precise location, and, critically, the enhancement pattern across arterial, portal venous, and delayed phases. Note whether there is washout, a capsule, or peripheral nodular enhancement, as these patterns help distinguish benign from malignant processes. Add diffusion-weighted imaging information with an ADC assessment, since diffusion restriction often reflects higher cellularity and favors malignancy, while lack of restriction can support benign etiologies. If liver-specific or hepatobiliary contrast is used, indicate whether the lesion takes up contrast in the hepatobiliary phase, which can further separate entities like focal nodular hyperplasia, adenoma, and malignancies. When features are indeterminate after initial imaging, recommend follow-up imaging or additional MRI sequences to improve characterization. Relying on size alone or omitting diffusion information deprives the radiology report of essential data that drive accurate characterization and appropriate follow-up.

Describing liver lesions on CT or MRI must be comprehensive and systematic, because imaging features across phases guide diagnosis and management. The most informative report includes lesion size and number, precise location, and, critically, the enhancement pattern across arterial, portal venous, and delayed phases. Note whether there is washout, a capsule, or peripheral nodular enhancement, as these patterns help distinguish benign from malignant processes. Add diffusion-weighted imaging information with an ADC assessment, since diffusion restriction often reflects higher cellularity and favors malignancy, while lack of restriction can support benign etiologies. If liver-specific or hepatobiliary contrast is used, indicate whether the lesion takes up contrast in the hepatobiliary phase, which can further separate entities like focal nodular hyperplasia, adenoma, and malignancies. When features are indeterminate after initial imaging, recommend follow-up imaging or additional MRI sequences to improve characterization. Relying on size alone or omitting diffusion information deprives the radiology report of essential data that drive accurate characterization and appropriate follow-up.